ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1601547
This article is part of the Research TopicImmune Predictive and Prognostic Biomarkers in Immuno-Oncology: Refining the Immunological Landscape of CancerView all 24 articles
The Function of CD164 in Breast Cancer and Its Possibility as a Molecular Biomarker: Bioinformatics Analysis and Experimental Validation
Provisionally accepted
- 1First Affiliated Hospital of Jilin University, Changchun, China
- 2College of Basic Medical Sciences, Jilin University, Changchun, Jilin Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Breast cancer is the most prevalent malignancy among women globally. Molecular targeted therapy improves treatment efficacy by precisely targeting tumor-specific molecules, minimizing damage to healthy tissues. Identifying new molecular targets is essential for enhancing therapeutic outcomes and prognosis in breast cancer.TCGA database was used to assess CD164 expression in breast cancer and its correlation with prognosis. Chemosensitivity analysis was performed to evaluate the association between CD164 and response to targeted therapies. Immune infiltration analysis was conducted to assess the relationship between CD164 expression and immune cell populations. CCK-8 assays, clonogenic assays and flow cytometry analyses were employed to examine the effects of CD164 knockdown on cell viability, proliferation, cell cycle progression, and apoptosis. RNA sequencing and gene set enrichment analysis (GSEA) was performed to identified pathways regulated by CD164.CD164 was highly expressed in breast cancer tissues and correlated with poorer prognosis, including shorter disease-free and overall survival. Chemosensitivity analysis linked CD164 to sensitivity to multiple targeted therapies, suggesting its role in oncogenic pathways. Immune infiltration analysis revealed CD164's association with immunosuppressive cells, including resting CD4 memory T cells, M2 macrophages, and mast cells, while exhibiting a negative correlation with Tregs and NK cells, underscoring its significance in the immunosuppressive tumor microenvironment.CD164 knockdown inhibited cell viability, proliferation, and induced cell cycle arrest and apoptosis. RNA sequencing and GSEA showed CD164 regulates proliferation, metabolism, migration, and adhesion pathways, while suppressing tumor-promoting pathways and activating immune-related pathways.CD164 plays a critical role in breast cancer progression, influencing tumor growth, immune evasion, and therapeutic response. It represents a promising therapeutic target, offering potential for improving breast cancer treatment and prognosis.
Keywords: breast cancer, Molecular Targeted Therapy, CD164, immune microenvironment, Apoptosis
Received: 28 Mar 2025; Accepted: 12 Jun 2025.
Copyright: © 2025 Song, Li, Mao, Wang, Chen, Hong, Wang and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dong Song, First Affiliated Hospital of Jilin University, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.